674 related articles for article (PubMed ID: 34925359)
21. Safety and antibody response of the BNT162b2 SARS-CoV-2 vaccine in children aged 5-11 years with underlying diseases: A prospective observational study.
Funaki T; Yamada M; Miyake K; Ueno S; Myojin S; Aiba H; Matsui T; Ogimi C; Kato H; Miyairi I; Shoji K
J Infect Chemother; 2024 Aug; 30(8):773-779. PubMed ID: 38387787
[TBL] [Abstract][Full Text] [Related]
22. Anti-SARS-CoV-2 IgG antibody titer after BNT162b2 mRNA COVID-19 vaccination in Japanese patients who underwent renal replacement therapy, hemodialysis, peritoneal dialysis, and kidney transplantation.
Iwabuchi R; Harada M; Yamada A; Aomura D; Yamada Y; Sonoda K; Nakazawa H; Sakai K; Mizukami E; Hashimoto K; Kamijo Y
Clin Exp Nephrol; 2023 Aug; 27(8):660-671. PubMed ID: 37095343
[TBL] [Abstract][Full Text] [Related]
23. Reactogenicity of COVID-19 vaccine in hemodialysis patients: a single-center retrospective study.
Alfano G; Morisi N; Fontana F; Scarmignan R; Tonelli L; Ferri C; Montani M; Melluso A; Giovanella S; Ligabue G; Mori G; Franceschini E; Guaraldi G; Cappelli G; Magistroni R; Donati G
G Ital Nefrol; 2022 Apr; 39(2):. PubMed ID: 35470997
[No Abstract] [Full Text] [Related]
24. Antibody Responses after Two Doses of COVID-19 mRNA Vaccine in Dialysis and Kidney Transplantation Patients Recovered from SARS-CoV-2 Infection.
Cappuccilli M; Semprini S; Fabbri E; Fantini M; Bruno PF; Spazzoli A; Righini M; Flachi M; La Manna G; Sambri V; Mosconi G
Medicina (Kaunas); 2022 Jul; 58(7):. PubMed ID: 35888612
[No Abstract] [Full Text] [Related]
25. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida.
Giuliano AR; Lancet JE; Pilon-Thomas S; Dong N; Jain AG; Tan E; Ball S; Tworoger SS; Siegel EM; Whiting J; Mo Q; Cubitt CL; Dukes CW; Hensel JA; Keenan RJ; Hwu P
JAMA Oncol; 2022 May; 8(5):748-754. PubMed ID: 35266953
[TBL] [Abstract][Full Text] [Related]
27. Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial.
Jochum S; Kirste I; Hortsch S; Grunert VP; Legault H; Eichenlaub U; Kashlan B; Pajon R
Front Immunol; 2021; 12():798117. PubMed ID: 35126362
[TBL] [Abstract][Full Text] [Related]
28. Anti-S1/RBD-Specific Antibody Formation After SARS-CoV-2 Vaccination in Elderly Rheumatoid Arthritis Patients: Single-Center Prospective Observational Study.
Kang ES; Oh JS; Lee EJ; Hong S; Ahn SM; Lee CK; Yoo B; Kim YG
J Korean Med Sci; 2023 Apr; 38(14):e109. PubMed ID: 37038645
[TBL] [Abstract][Full Text] [Related]
29. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients.
Danthu C; Hantz S; Dahlem A; Duval M; Ba B; Guibbert M; El Ouafi Z; Ponsard S; Berrahal I; Achard JM; Bocquentin F; Allot V; Rerolle JP; Alain S; Touré F
J Am Soc Nephrol; 2021 Sep; 32(9):2153-2158. PubMed ID: 34135083
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
31. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
Reindl-Schwaighofer R; Heinzel A; Mayrdorfer M; Jabbour R; Hofbauer TM; Merrelaar A; Eder M; Regele F; Doberer K; Spechtl P; Aschauer C; Koblischke M; Paschen C; Eskandary F; Hu K; Öhler B; Bhandal A; Kleibenböck S; Jagoditsch RI; Reiskopf B; Heger F; Bond G; Böhmig GA; Strassl R; Weseslindtner L; Indra A; Aberle JH; Binder M; Oberbauer R
JAMA Intern Med; 2022 Feb; 182(2):165-171. PubMed ID: 34928302
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.
Ali K; Berman G; Zhou H; Deng W; Faughnan V; Coronado-Voges M; Ding B; Dooley J; Girard B; Hillebrand W; Pajon R; Miller JM; Leav B; McPhee R
N Engl J Med; 2021 Dec; 385(24):2241-2251. PubMed ID: 34379915
[TBL] [Abstract][Full Text] [Related]
33. A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
Masuda T; Murakami K; Sugiura K; Sakui S; Philip Schuring R; Mori M
Vaccine; 2022 Mar; 40(13):2044-2052. PubMed ID: 35177302
[TBL] [Abstract][Full Text] [Related]
34. Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients.
Yoshifuji A; Toda M; Oyama E; Nakayama T; Mise-Omata S; Kikuchi K; Yoshizawa M; Kato N; Wakai H; Koibuchi K; Morimoto K; Uwamino Y; Namkoong H; Shibata A; Wakabayashi K; Fujino M; Komatsu M; Mochizuki N; Kondo N; Yoshimura A; Hasegawa N; Ryuzaki M
Clin Exp Nephrol; 2024 Jul; 28(7):674-682. PubMed ID: 38457030
[TBL] [Abstract][Full Text] [Related]
35. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
Greenberg RS; Ruddy JA; Boyarsky BJ; Werbel WA; Garonzik-Wang JM; Segev DL; Imus PH
BMC Cancer; 2021 Dec; 21(1):1354. PubMed ID: 34961488
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and tolerability of COVID-19 vaccination in peritoneal dialysis patients-A prospective observational cohort study.
Haase M; Lesny P; Haase-Fielitz A; Anderson M; Cloherty G; Stec M; Lucas C; Santos-Araujo C; Haarhaus M; Macario F
Semin Dial; 2022 May; 35(3):269-277. PubMed ID: 34854131
[TBL] [Abstract][Full Text] [Related]
37. Humoral Response to mRNA-1273 SARS-CoV-2 Vaccine in Peritoneal Dialysis Patients: Is Boostering After Six Months Adequate?
Beilhack G; Monteforte R; Frommlet F; Reindl-Schwaighofer R; Strassl R; Vychytil A
Front Med (Lausanne); 2022; 9():905798. PubMed ID: 35814775
[TBL] [Abstract][Full Text] [Related]
38. SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan.
Kanai D; Wakui H; Haze T; Azushima K; Kinguchi S; Tsukamoto S; Kanaoka T; Urate S; Toya Y; Hirawa N; Kato H; Watanabe F; Hanaoka K; Hanaoka M; Mitsuhashi H; Yamaguchi S; Ohnishi T; Tamura K
Clin Exp Nephrol; 2022 Oct; 26(10):988-996. PubMed ID: 35751753
[TBL] [Abstract][Full Text] [Related]
39. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
Jackson LA; Anderson EJ; Rouphael NG; Roberts PC; Makhene M; Coler RN; McCullough MP; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott A; Flach B; Doria-Rose NA; Corbett KS; Morabito KM; O'Dell S; Schmidt SD; Swanson PA; Padilla M; Mascola JR; Neuzil KM; Bennett H; Sun W; Peters E; Makowski M; Albert J; Cross K; Buchanan W; Pikaart-Tautges R; Ledgerwood JE; Graham BS; Beigel JH;
N Engl J Med; 2020 Nov; 383(20):1920-1931. PubMed ID: 32663912
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Mittal A; Solera JT; Ferreira VH; Kothari S; Kimura M; Pasic I; Mattsson JI; Humar A; Kulasingam V; Ierullo M; Kumar D; Hosseini-Moghaddam SM
Transplant Cell Ther; 2023 Nov; 29(11):706.e1-706.e7. PubMed ID: 37582470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]